Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenSpera has dosed first patient in an open -label, dose-escalation Phase I clinical study of G-202, the company's chemotherapeutic agent, at the Cancer Therapy & Research Center (CTRC), at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.
Subscribe to our email newsletter
The primary endpoint of the trial is to determine the safety, tolerability and pharmacokinetics of the drug, although the design allows the collection of efficacy data as well.
The trial also has the provision to recruit up to 18 additional patients in an expanded Phase Ib cohort at the maximum tolerated dose of the drug.
Principal investigator of the study Devalingam Mahalingam said G-202 has shown much promise in pre-clinical testing, so he is hopeful it will show good clinical activity in my patients.
GenSpera president and CEO Craig Dionne said they have carefully selected their clinical hospitals for both their expertise and to reach a cross-section of patients, and are pleased to bring this third center of excellence into the trial.